Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ilaris
Pharma
Novartis' Ilaris fails 3rd trial in lung cancer
The drug didn't show improvement compared with placebo in disease-free survival, missing the study's primary endpoint.
Zoey Becker
Aug 15, 2022 11:26am
AACR: Novartis makes case for canakinumab in lung cancer
Apr 12, 2022 4:05pm
Novartis looks for silver lining after 2nd Ilaris NSCLC flop
Oct 25, 2021 10:45am
Novartis says it overpaid Genentech nearly $210M in IP
Jun 28, 2021 11:18am
Novartis chalks up a flop for canakinumab in NSCLC
Mar 9, 2021 10:35am
Inside Novartis' fight to keep its supply chain open amid COVID
Jun 4, 2020 11:20am
